ALPHAMAB ONCOLO.DL-000002 (3NK) - Total Assets
Based on the latest financial reports, ALPHAMAB ONCOLO.DL-000002 (3NK) holds total assets worth €2.10 Billion EUR (≈ $2.45 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ALPHAMAB ONCOLO.DL-000002 - Total Assets Trend (2021–2025)
This chart illustrates how ALPHAMAB ONCOLO.DL-000002's total assets have evolved over time, based on quarterly financial data. Also see market value of ALPHAMAB ONCOLO.DL-000002 for the company's overall valuation and market capitalisation.
ALPHAMAB ONCOLO.DL-000002 - Asset Composition Analysis
Current Asset Composition (December 2025)
ALPHAMAB ONCOLO.DL-000002's total assets of €2.10 Billion consist of 76.0% current assets and 24.0% non-current assets. Review ALPHAMAB ONCOLO.DL-000002 balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.3% |
| Accounts Receivable | €61.95 Million | 3.0% |
| Inventory | €107.88 Million | 5.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €19.70 Million | 0.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ALPHAMAB ONCOLO.DL-000002's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest ALPHAMAB ONCOLO.DL-000002 stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALPHAMAB ONCOLO.DL-000002's current assets represent 76.0% of total assets in 2025, a decrease from 78.2% in 2021.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2025, down from 29.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 5.1% of total assets.
ALPHAMAB ONCOLO.DL-000002 Competitors by Total Assets
Key competitors of ALPHAMAB ONCOLO.DL-000002 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
ALPHAMAB ONCOLO.DL-000002 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.67 | 6.74 | 4.61 |
| Quick Ratio | 5.29 | 6.41 | 4.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.31 Billion | €1.46 Billion | €1.25 Billion |
ALPHAMAB ONCOLO.DL-000002 - Advanced Valuation Insights
This section examines the relationship between ALPHAMAB ONCOLO.DL-000002's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.02 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -6.5% |
| Total Assets | €2.10 Billion |
| Market Capitalization | $876.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values ALPHAMAB ONCOLO.DL-000002's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ALPHAMAB ONCOLO.DL-000002's assets decreased by 6.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below shows the annual total assets of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.10 Billion ≈ $2.45 Billion |
-6.45% |
| 2024-12-31 | €2.24 Billion ≈ $2.62 Billion |
+4.90% |
| 2023-12-31 | €2.14 Billion ≈ $2.50 Billion |
+0.92% |
| 2022-12-31 | €2.12 Billion ≈ $2.48 Billion |
-21.72% |
| 2021-12-31 | €2.71 Billion ≈ $3.16 Billion |
-- |
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under th… Read more